MedinCell S.A. MDCLF
34.39 USD 0.00 (+0.00%)
At closeFeb 5, 2026, 4:00 PM EST
6.98 Day range 6.98
6.98 52-week range 34.39
- YTD
- +392.69%
- 1 year
- +392.69%
News
businesswire.com Medincell Brings Total Non-Dilutive Financing Secured Since July 2026 to €41.8 Million with an Additional €13.8 Million Loan MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Euronext Paris: MEDCL) today announced that it has secured an additional €13.8 million in non-dilutive financing from leading European commercial…
seekingalpha.com MedinCell S.A. (MDCLF) Discusses U.S. Approval of Weltruza and Its Impact on Schizophrenia Treatment and Financial Outlook Transcript MedinCell S.A. (MDCLF) Discusses U.S. Approval of Weltruza and Its Impact on Schizophrenia Treatment and Financial Outlook Transcript
businesswire.com Medincell Achieves Major Milestone with U.S. FDA Approval of WELTRUZA™ (olanzapine) MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Paris:MEDCL): Medincell will host Investor webcast today to discuss the implications of the approval for the Company and answer…
businesswire.com Medincell's Partner Teva Presented New Data on Investigational Olanzapine LAI and UZEDY® at Psych Congress 2026 MONTPELLIER, France--(BUSINESS WIRE)--Medincell's partner Teva presented new data on investigational Olanzapine long-acting injectable (LAI) and UZEDY®, two treatments utilizing Medincell's…
businesswire.com Medincell to Participate in Upcoming Investor Conferences MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today…
businesswire.com Medincell: Publication of the Notice of Meeting and Reminder of the Participation terms in the Combined General Meeting MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Paris:MEDCL): The Annual General Meeting and Extraordinary General Meeting will be held at Medincell's headquarters (3 rue des Frères…
businesswire.com Medincell Appoints Edna Venneker, MD, as Chief Medical Officer MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Euronext: MEDCL), a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable treatments across multiple…
businesswire.com Medincell's Dr Grace Kim to Participate in Piper Sandler CNS Symposium MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Euronext Paris: MEDCL), a clinical- and commercial-stage innovation-driven biopharmaceutical company developing and licensing long-acting injectable…
businesswire.com Medincell: UZEDY®: Record Q2 Net Sales of $77M, Up 43% YoY; Teva Raises 2026 Outlook MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a…
businesswire.com Medincell Continues to Strengthen and Renew its Board of Directors with the Proposed Appointment of Dr. Elisabeth Svanberg MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Euronext Paris: MEDCL) today announced that its Board of Directors will propose the appointment of Dr. Elisabeth Svanberg as an independent director…
businesswire.com Medincell Aligns Debt Maturity with Its Expected Revenue Growth Trajectory MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Euronext Paris: MEDCL) today announced the completion of non-dilutive financing transactions designed to strengthen its financing profile and align…
seekingalpha.com MedinCell S.A. (MDCLF) Q4 2026 Earnings Call Transcript MedinCell S.A. (MDCLF) Q4 2026 Earnings Call Transcript
businesswire.com Medincell Reports FY 2025-26 Annual Results MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Paris:MEDCL): Key Financial Highlights Total revenues €24.3 million, including €9.3 million of UZEDY® royalties, confirming the evolution of the…
businesswire.com Medincell: Videoconference and Publication of Annual Financial Results, Tuesday, June 16, 2026 MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today…
businesswire.com Medincell to Participate in Jefferies and Evercore Investor Conferences in the U.S. in June MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable…
seekingalpha.com MedinCell S.A. (MDCLF) Discusses Long-Acting Injectable Platform, R&D Strategy, and Value Creation Approach Transcript MedinCell S.A. (MDCLF) Discusses Long-Acting Injectable Platform, R&D Strategy, and Value Creation Approach Transcript
businesswire.com Medincell to Host an Online R&D Day on Tuesday, May 12, 2026 MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Euronext Paris: MEDCL) will host an online R&D Day, held in English, on Tuesday, May 12, 2026, from 4:00 to 5:30 pm CEST (10:00 -…
businesswire.com Medincell to Present at the TD Cowen 46th Annual Healthcare Conference in Boston, March 2-4, 2026 MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable…
businesswire.com Medincell - UZEDY®: Net Sales Increased from $117M in 2024 to $191M in 2025 (+63%) MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell's (Paris:MEDCL) partner, Teva Pharmaceuticals, today shared the following information in connection with the publication of its Q4 and…
seekingalpha.com MedinCell S.A. (MDCLF) Q2 2026 Earnings Call Transcript MedinCell S.A. (MDCLF) Q2 2026 Earnings Call Transcript